2 results
Approved WMORecruiting
The purpose of this clinical study is the assessment of the safety and effectiveness of the Flex II PFO Occluder in the treatment of subjects 18 years of age or older who have had a cryptogenic stroke due to a presumed paradoxical embolism as…
Approved WMORecruiting
Primary• To evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first line treatment) as measured by Progression Free Survival (PFS) in subjects with Claudin (CLDN) 18.2-positive,…